A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; PT 2977 (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Peloton Therapeutics
- 24 Sep 2019 Status changed from active, no longer recruiting to recruiting.
- 16 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2018 Status changed from not yet recruiting to recruiting.